|
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
|
|
W24-025-2
|
|
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
|
|
Dr. Andrew Winokur
|
|
This is a clinical study of an investigational medication for adults with Major Depressive Disorder (MDD). The purpose of the study is to evaluate the effectiveness of REL-1017 when used as an add-on treatment for adults with MDD. Study participation lasts 8 weeks and includes a screening phase, a double blinded phase and a follow-up phase.
|
Psychiatry - General Adult/Mental Health (Depression, Anxiety, Etc.)
|
|
|
Adults 18-65 years of age; have a diagnosis of MDD; have not responded adequately to up to 3 different antidepressants in the current depressive episode; for additional eligibility criteria, check in with study contact.
|
|
Galina Prpich. Telephone: 860-679-7539 Email: prpich@uchc.edu
|
|
Enrolling/recruiting
|
|
|